Table 4. Multivariate analysis of transplantation outcome in TBF-MAC vs BF-MAC with selected busulfan dose.

Outcome		HR	95% CI	P
Relapse	TBF vs BF	0.45	0.25–0.83	0.01
	Patient age per 10 years	1.13	1.02–1.25	0.02
	Secondary AML	1.25	0.88–1.77	0.2
	URD vs MSD	1.11	0.81–1.52	0.49
	Female donor to male recipient	0.96	0.72–1.29	0.8
	In-vivo TCD	0.82	0.62–1.09	0.19
	PBSC vs BM	0.96	0.72–1.29	0.81
	centre (frailty)			0.69
NRM	TBF vs BF	1.53	0.89–2.6	0.12
	Patient age per 10 years	1.57	1.35–1.82	<10–5
	Secondary AML	0.88	0.56–1.38	0.58
	URD vs MSD	1.61	1.08–2.38	0.02
	Female donor to male recipient	1.12	0.79–1.58	0.53
	In-vivo TCD	0.814	0.562–1.177	0.27
	PBSC vs BM	1.94	1.21–3.12	0.006
	centre (frailty)			0.004
LFS	TBF vs BF	0.82	0.56–1.2	0.31
	Patient age per 10 years	1.26	1.16–1.38	<10–5
	Secondary AML	1.08	0.82–1.42	0.59
	URD vs MSD	1.27	0.99–1.61	0.059
	Female donor to male recipient	1.03	0.82–1.29	0.79
	In-vivo TCD	0.8	0.63–1.01	0.05
	PBSC vs BM	1.27	0.98–1.64	0.07
	centre (frailty)			0.22
OS	TBF vs BF	0.95	0.63–1.44	0.82
	Patient age per 10 years	1.32	1.19–1.45	<10–5
	Secondary AML	0.99	0.73–1.33	0.92
	URD vs MSD	1.21	0.92–1.58	0.17
	Female donor to male recipient	1.02	0.81–1.3	0.85
	In-vivo TCD	0.82	0.64–1.06	0.13
	PBSC vs BM	1.37	1.03–1.82	0.03
	centre (frailty)			0.14
GRFS	TBF vs BF	0.78	0.54–1.126	0.18
	Patient age per 10 years	1.21	1.118–1.319	<10–5
	Secondary AML	1.04	0.807–1.344	0.76
	URD vs MSD	1.21	0.963–1.52	0.10
	Female donor to male recipient	1.25	1.027–1.517	0.76
	In-vivo TCD	0.75	0.595–0.933	0.01
	PBSC vs BM	1.29	1.007–1.663	0.04
	centre (frailty)			0.02